Journal · Skin Concerns

GLP-1 and Ozempic Skin Changes: What Is Documented and What Is Not Tested

GLP-1 skin changes documented in reviews: facial volume loss, telogen effluvium shedding, injection-site and hypersensitivity reactions. No tested fix exists.

Skin changes on GLP-1 medications are mostly downstream of rapid weight loss. Published reviews document facial volume loss, hair shedding that fits telogen effluvium, injection-site reactions, and hypersensitivity rashes such as hives. No skincare product has been tested as a countermeasure for any of them.

What skin changes are documented on GLP-1 medications?

Key Takeaways

Facial volume loss is measurable: roughly 7% of midfacial volume per 10 kg of body weight lost 3.
Hair shedding on these drugs usually looks like telogen effluvium, a shedding phase set off by rapid weight loss 78.
Injection-site reactions, itching, hives and rarer immune-mediated eruptions are documented across reviews 12.
Some inflammatory skin conditions may improve on treatment, though that evidence is early 1.
Nothing in skincare has been tested against any of it, so every routine change here is supportive care.

A systematic review of the dermatologic literature pulled 51 studies. Thirty-four of them reported adverse effects: hypersensitivity, injection-site reactions, itching, hives, angioedema, and immune-mediated conditions including bullous pemphigoid. Seventeen reported benefits instead 1.

The effects are real and varied, and almost none of them are the kind of thing a serum addresses. A review from a hair-specialist group sorts the same findings into injection-site reactions, immune-mediated responses, facial fat loss and telogen effluvium 2.

None of this is medical advice. If a skin change worries you, call the person who prescribed the medication.

Why does the face change shape on GLP-1 medications?

Fat does not leave the body evenly, and the face carries superficial fat pads that show it early. A retrospective cohort at one academic center imaged 20 patients before and after starting a GLP-1 agonist. Median total midfacial volume fell 9.0%, superficial volume fell 11.0%, and regression put the relationship at roughly 7% of facial volume lost for every 10 kg of body weight lost 3.

The weight changes behind that are large. In the STEP 1 trial, mean body weight fell 14.9% over 68 weeks on semaglutide 2.4 mg 4. In SURMOUNT-1, the highest tirzepatide dose averaged 20.9% over 72 weeks 5. Skin that was draped over more volume now has less underneath it, and the result is softer contour along the cheeks and jaw.

Volume may not be the only factor. One mechanistic review proposes that GLP-1 receptors on fibroblasts and adipose-derived stem cells could reduce protective cytokine signaling and collagen production, which would affect dermal structure directly 6. Its own conclusion is that these mechanisms still have to be worked out. Hypothesis stage, and not a reason to buy anything.

Is hair loss on GLP-1 medications real, and does it grow back?

Hair shedding shows up often enough to take seriously. A 2026 systematic review screened 133 studies and included 24. Semaglutide and tirzepatide carried the highest reported hair-loss incidence of the GLP-1 drugs. Telogen effluvium and androgenetic alopecia were the predominant subtypes, women appeared disproportionately affected, and rapid weight loss stood out as a likely contributor, particularly for telogen effluvium 7.

Telogen effluvium is the pattern worth understanding. It is diffuse, non-scarring shedding usually set off by a physiological stress such as sudden weight loss, and it has a high rate of remission. It also has no targeted treatment 8.

That is annoying and reassuring at once. Hair generally recovers once the trigger settles, and no product has been shown to speed that up here. A dermatologist can confirm it is telogen effluvium and not something that needs its own workup, which matters if it fails to settle after several months or arrives with patches or scalp pain.

What about dryness, itching and injection-site reactions?

Injection-site reactions and itching are the best-documented minor effects. They appear across the review literature and across trial programs, with tirzepatide's rates in the SURPASS trials described as comparable to other GLP-1 drugs 19. Hives, swelling and rarer immune-mediated eruptions sit on the same list 12.

Dryness is the change people report most and the one with the least published backing. It is not a characterized endpoint in any of these reviews. Reduced intake is the plausible route: a 2026 review describes how eating less, narrower food variety, delayed gastric emptying and rapid weight loss interact to put iron, vitamin B12, vitamin D, zinc and magnesium under pressure, with most reported abnormalities still subclinical 10.

Iron, B12 and zinc all matter for hair and skin. That makes intake a question for a blood test and your prescriber, not for a serum. Ask about protein and micronutrient adequacy at your next appointment.

Can GLP-1 medications improve skin conditions?

Seventeen of those 51 studies reported benefits: improvement in psoriasis, fewer hidradenitis suppurativa flares, better wound healing and reduced inflammation, with cytokine modulation proposed as the psoriasis mechanism. The same review calls the hidradenitis suppurativa role uncertain 1. A tirzepatide review lands in the same place, noting that the immunomodulatory case rests on case reports and small studies 9.

Acne is a gap. None of the major reviews describe a consistent acne signal in either direction, so anyone telling you these medications clear or cause breakouts is ahead of the evidence.

Skin is not a reason to start or stay on a GLP-1 medication. That is a metabolic decision between you and your prescriber.

Has any skincare product been tested against GLP-1 skin changes?

No. There are no published trials of a moisturizer, serum, scalp product or supplement tested in people taking GLP-1 medications for any of these changes. Every review in this area ends by asking for mechanistic work and long-term safety data 1279, and telogen effluvium has no targeted treatment even outside this context 8.

The realistic ceiling for skincare is supportive: keep the barrier comfortable while the rest of the body does something dramatic. Bland and consistent beats a new active every week.

Humectants such as glycerin and hyaluronic acid pull water into the surface layers. Occlusives and emollients such as squalane, petrolatum and ceramides slow the water back out. A non-stripping cleanser stops you undoing both. Our guide to barrier repair moisturizer ratios covers what those formulas look like on a label, and the skin barrier repair guide covers the timeline.

If you use retinoids or exfoliating acids, this is a sensible stretch to go low and slow. Patch test anything new on the inner arm, add one product at a time, and wear SPF every day.

Which symptoms need supportive care and which need a clinician?

Sorting the two saves money and worry.

Symptom What the evidence says Supportive care Talk to a clinician if
Facial volume loss, looser drape Measurable: roughly 7% of midface volume per 10 kg lost 3 Barrier support and daily SPF; procedures are a separate decision You are weighing fillers or surgery
Diffuse hair shedding Fits telogen effluvium, linked to rapid weight loss, high remission rate 78 Gentle handling; protein and micronutrient adequacy through your prescriber Shedding does not settle after several months, or patches or scalp pain appear
Dryness and tightness Not a characterized endpoint; plausibly tied to reduced intake 10 Humectant plus occlusive twice daily, non-stripping cleanser Skin cracks, weeps, or develops eczema-like plaques
Injection-site redness or itch Documented across reviews and trial programs 19 Nothing topical is validated; keep the area clean It spreads, blisters, or lasts more than a few days
Hives, swelling, blistering rash Hypersensitivity and bullous pemphigoid reported 12 None; this one is not a skincare problem Straight away. Lip, tongue or throat swelling is an emergency

Use This in Your Routine

Two Skin Bliss features fit the titration weeks, when your dose is stepping up. Log Skin Changes, Mood & Notes gives you a dated record of tightness, shedding and injection-site irritation, so you can tell your prescriber what happened in which week. The AI Progress Tracker compares new photos against your original Face Scan and may surface slow shifts in dryness or redness that daily mirror checks miss.

Skin Bliss is a skincare scanner that checks whether products actually fit your skin, before you buy. If you are simplifying down to a cleanser, a humectant and an occlusive, that is a good moment to check what is already on your shelf at getskinbliss.com.

Save this one for the week your dose goes up. If your skin does something new, write down what and when, then bring it to the person who prescribed the medication.

FAQ

Does facial volume loss on GLP-1 medications come back if you stop?

Nobody has published the follow-up. The imaging cohort measured midfacial volume during treatment, not after stopping, so what happens to facial fat distribution afterwards has not been studied in this group 3. Ask your prescriber, and get a qualified clinician involved before committing to any procedure aimed at restoring volume.

Will hair shedding on a GLP-1 medication grow back?

Usually. The shedding reported on these drugs fits telogen effluvium, which has a high rate of remission once the trigger settles, although no targeted treatment exists to speed it up 78. Rapid weight loss stands out as the likely contributor 7. See a dermatologist if it drags on or comes with patches or scalp symptoms.

What moisturizer should you use while taking a GLP-1 medication?

Nothing has been tested in this population, so a plain barrier-supporting routine is the sensible default: a non-stripping cleanser, a humectant layer such as glycerin or hyaluronic acid, and an occlusive or emollient over it. Ceramide-containing moisturizers are a reasonable pick. Keep actives low and slow while your body is handling a large metabolic change, and wear SPF daily.

Should you take collagen or biotin supplements for GLP-1 hair shedding?

Neither has been tested in people on GLP-1 medications. Our review of collagen supplements and lifestyle habits notes that some of the positive trials were funded by supplement companies. A 2026 review of micronutrient risk on these drugs points at iron, vitamin B12, vitamin D and zinc as the things worth checking, through your prescriber and a blood test 10.

Is injection-site irritation a sign of an allergy?

Usually not. Injection-site reactions are among the most commonly documented skin effects of these medications and are local by definition 19. Hives, swelling or a spreading rash belong in a different category and deserve a same-day call to your prescriber. Swelling of the lips, tongue or throat is an emergency.

In your browser

Free Skin Quiz: Understand your skin profile in under 5 minutes

Oily or dry is only the start. Find out what your skin actually needs across six skin dimensions, with a plain note on what each one means for your routine. Results appear in your browser, and you can keep them in the app.

Maria Otworowska, PhD Co-founder of Skin Bliss · PhD in Computational Cognitive Science & AI

Maria combines her background in AI research with a passion for evidence-based skincare. She built Skin Bliss to help people make informed decisions about their skin, backed by science rather than marketing.

Sources (10)
  1. Persson C, Eaton A, Mayrovitz HN (2025). "A Closer Look at the Dermatological Profile of GLP-1 Agonists." *Diseases*.
  2. Burke OM et al. (2025). "Dermatologic Implications of Glucagon-Like Peptide-1 Receptor Agonist Medications." *Skin Appendage Disord*.
  3. Sharma RK et al. (2025). "Radiographic Midfacial Volume Changes in Patients on GLP-1 Agonists." *Otolaryngol Head Neck Surg*.
  4. Wilding JPH et al. (2021). "Once-Weekly Semaglutide in Adults with Overweight or Obesity." *N Engl J Med*.
  5. Jastreboff AM et al. (2022). "Tirzepatide Once Weekly for the Treatment of Obesity." *N Engl J Med*.
  6. Paschou IA et al. (2025). "GLP-1RA and the possible skin aging." *Endocrine*.
  7. Gupta AK et al. (2026). "GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling." *Sci Prog*.
  8. Chien Yin GO et al. (2021). "Telogen Effluvium - a review of the science and current obstacles." *J Dermatol Sci*.
  9. El-Amawy HS (2026). "Tirzepatide in dermatology: cutaneous adverse events, emerging therapeutic roles, and cosmetic implications - A comprehensive review." *An Bras Dermatol*.
  10. Simancas-Racines D et al. (2026). "Micronutrient risk with GLP-1 receptor and dual incretin agonists in obesity: Mechanistic pathways, clinical signals, and a monitoring framework." *Obes Pillars*.